Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Barraclough

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 28, 2010
Biostatistics primer: what a clinician ought to know: subgroup analysesHelen Barraclough, Ramaswamy Govindan
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 17, 2013
Biostatistics primer: what a clinician ought to know--prognostic and predictive factorsLorinda Simms, Helen Barraclough, Ramaswamy Govindan
Journal of Molecular Evolution|November 30, 2005
Evolutionary relationships and protein domain architecture in an expanded calpain superfamily in kinetoplastid parasitesKlaus Ersfeld, Helen Barraclough, Keith Gull
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 31, 2011
Biostatistics primer: what a clinician ought to know: hazard ratiosHelen Barraclough, Lorinda Simms, Ramaswamy Govindan
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 7, 2014
In responseHelen Barraclough, Lorinda Simms, Ramaswamy Govindan
Gynecologic Oncology Reports|June 16, 2015
Cost effectiveness of concurrent gemcitabine and cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in stages IIB-IVA cervical cancerNarayan Rajan, Helen Barraclough, Tarun Puri, et al.
Drugs in R&D|November 27, 2013
Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancerJosé Rodrigues Pereira, Rebecca Cheng, Mauro Orlando, et al.
Australian and New Zealand Journal of Public Health|October 31, 2008
Degree-of-spread artefact in the New South Wales Central Cancer RegistryHelen Barraclough, Stephen Morrell, Maria Arcorace, et al.
Respirology (Carlton, Vic.)|August 2, 2011
Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidenceLachlan Standfield, Adèle R Weston, Helen Barraclough, et al.
World Journal of Diabetes|November 30, 2016
Relationship between depression and diabetes in pregnancy: A systematic reviewGlynis P Ross, Henrik Falhammar, Roger Chen, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 28, 2010
Biostatistics primer: what a clinician ought to know: subgroup analysesHelen Barraclough, Ramaswamy Govindan
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 17, 2013
Biostatistics primer: what a clinician ought to know--prognostic and predictive factorsLorinda Simms, Helen Barraclough, Ramaswamy Govindan
Journal of Molecular Evolution|November 30, 2005
Evolutionary relationships and protein domain architecture in an expanded calpain superfamily in kinetoplastid parasitesKlaus Ersfeld, Helen Barraclough, Keith Gull
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 31, 2011
Biostatistics primer: what a clinician ought to know: hazard ratiosHelen Barraclough, Lorinda Simms, Ramaswamy Govindan
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 7, 2014
In responseHelen Barraclough, Lorinda Simms, Ramaswamy Govindan
Gynecologic Oncology Reports|June 16, 2015
Cost effectiveness of concurrent gemcitabine and cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in stages IIB-IVA cervical cancerNarayan Rajan, Helen Barraclough, Tarun Puri, et al.
Drugs in R&D|November 27, 2013
Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancerJosé Rodrigues Pereira, Rebecca Cheng, Mauro Orlando, et al.
Australian and New Zealand Journal of Public Health|October 31, 2008
Degree-of-spread artefact in the New South Wales Central Cancer RegistryHelen Barraclough, Stephen Morrell, Maria Arcorace, et al.
Respirology (Carlton, Vic.)|August 2, 2011
Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidenceLachlan Standfield, Adèle R Weston, Helen Barraclough, et al.
World Journal of Diabetes|November 30, 2016
Relationship between depression and diabetes in pregnancy: A systematic reviewGlynis P Ross, Henrik Falhammar, Roger Chen, et al.
Pageof 3